

Notice of Results

Released : 12/09/2022 07:00

RNS Number : 0161Z
Celadon Pharmaceuticals PLC
12 September 2022



Celadon Pharmaceuticals Plc

("Celadon" or the "Company")

Notice of Results and Investor Presentation

LONDON, 12 September 2022: Celadon Pharmaceuticals Plc (AIM: CEL), a leading UK based pharmaceutical company focused on the development and supply of natural cannabis-based medicines, will announce its maiden results for the six months ended 30 June 2022 on Thursday 29 September 2022.

Analyst Briefing: 9.00am, Thursday 29 September 2022

Management will host a virtual analyst presentation followed by a Q&A session at 9.00am BST on Thursday 29 September 2022. Analysts wishing to join should register their interest by contacting celadon@powerscourt-group.com.

Investor Presentation: 2.30pm, Thursday 29 September 2022

Management will be hosting a live presentation and Q&A session via the online platform, Investor Meet Company, at 2.30pm BST on Thursday 29 September 2022.

The presentation is open to analysts and all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9.00am on Thursday 29 September 2022 or at any time during the live presentation. Investors can sign up to Investor Meet Company for free via: <https://www.investormeetcompany.com/celadon-pharmaceuticals-plc/register-investor>

Investors who already follow Celadon on the Investor Meet Company platform will automatically receive an invitation to the event.

Enquiries:
Celadon Pharmaceuticals Plc
James Short
Arthur Wakeley

Via Powerscourt

Canaccord Genuity Limited (Nominated Adviser and Broker)

Andrew Potts / Patrick Dolaghan / Bobbie Hilliam

+44 (0)20 7523 8000

Powerscourt Group

Sarah MacLeod / Nick Johnson / Sam Austrums /
Ibrahim Khalil

+44 (0)20 7250 1446

celadon@powerscourt-group.com

About Celadon Pharmaceuticals Plc

Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and supply of natural cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility comprises a laboratory designed to meet GMP standards, and capacity for a large indoor hydroponic growing facility that has received a Home Office License to legally grow high-THC medicinal cannabis for the purpose of producing test batches of cannabis oil to support its application to the MHRA. The Company's subsidiary, LVL, owns a MHRA conditionally-approved cannabis trial using cannabis based medicinal products to treat chronic pain in the UK.

For further information please visit our website www.celadonpharma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORBGDCBBBDGDB